The topography of plaques and tangles in Down's syndrome patients of different ages
- PMID: 2946973
- DOI: 10.1111/j.1365-2990.1986.tb00053.x
The topography of plaques and tangles in Down's syndrome patients of different ages
Abstract
The topographical distribution of senile plaques and neurofibrillary tangles has been investigated in 12 patients with Down's syndrome ranging from 31 to 65 years of age. No plaques or tangles whatsoever were seen in the brain of the 31-year-old patient. The nine patients over 53 years of age, showed a similar pathological picture in which there were numerous mature plaques in all areas of cerebral cortex, hippocampus and amygdala and numerous tangles in these areas and in subcortical structures such as nucleus basalis, locus caeruleus, dorsal raphe, ventral tegmental area, substantia nigra, olfactory bulb and tracts. In the other two patients aged 37 and 51 years, an intermediate pathological picture was seen in which primitive plaques predominated within the cortex, with numerous mature plaques in hippocampus and amygdala. In the 37-year-old patient, tangles were numerous in the entorhinal cortex, but much less common in hippocampus and amygdala, rare in cerebral cortex and absent in the subcortical areas, olfactory bulbs and tracts. A similar pattern was seen in the 51-year-old patient though here some cells in the subcortex were also affected. These observations suggest that the primary focus of plaque and tangle formation in Down's syndrome may be in amygdala, entorhinal cortex and hippocampus, with a 'spreading out' to subsequently involve all areas of cortex, certain subcortical regions and the olfactory bulbs and tracts. It appears unlikely that the olfactory bulbs and tracts provide a portal of entry for any pathogenic agent that may be responsible for inducing plaque and tangle formation within the rest of the brain.
Similar articles
-
Alzheimer's disease: an olfactory connection?Mech Ageing Dev. 1988 Jan;42(1):1-15. doi: 10.1016/0047-6374(88)90058-9. Mech Ageing Dev. 1988. PMID: 2964546
-
The amygdala in Down's syndrome and familial Alzheimer's disease: four clinicopathological case reports.Biol Psychiatry. 1991 Jul 1;30(1):92-106. doi: 10.1016/0006-3223(91)90075-w. Biol Psychiatry. 1991. PMID: 1832566
-
Loss of neurones from cortical and subcortical areas in Down's syndrome patients at middle age. Quantitative comparisons with younger Down's patients and patients with Alzheimer's disease.J Neurol Sci. 1987 Aug;80(1):79-89. doi: 10.1016/0022-510x(87)90223-1. J Neurol Sci. 1987. PMID: 2956368
-
An integrative hypothesis concerning the pathogenesis and progression of Alzheimer's disease.Neurobiol Aging. 1986 Nov-Dec;7(6):489-502. doi: 10.1016/0197-4580(86)90086-2. Neurobiol Aging. 1986. PMID: 2882432 Review.
-
Alzheimer's disease and Down's syndrome.Histopathology. 1988 Aug;13(2):125-37. doi: 10.1111/j.1365-2559.1988.tb02018.x. Histopathology. 1988. PMID: 2971602 Review.
Cited by
-
Human cystatin C induces the disaggregation process of selected amyloid beta peptides: a structural and kinetic view.Sci Rep. 2023 Nov 27;13(1):20833. doi: 10.1038/s41598-023-47514-w. Sci Rep. 2023. PMID: 38012338 Free PMC article.
-
Basal forebrain cholinergic neurons are vulnerable in a mouse model of Down syndrome and their molecular fingerprint is rescued by maternal choline supplementation.FASEB J. 2023 Jun;37(6):e22944. doi: 10.1096/fj.202202111RR. FASEB J. 2023. PMID: 37191946 Free PMC article.
-
RNAseq analysis of olfactory neuroepithelium cytological samples in individuals with Down syndrome compared to euploid controls: a pilot study.Neurol Sci. 2023 Mar;44(3):919-930. doi: 10.1007/s10072-022-06500-2. Epub 2022 Nov 17. Neurol Sci. 2023. PMID: 36394661 Free PMC article.
-
Amyloid- β and tau deposition influences cognitive and functional decline in Down syndrome.Neurobiol Aging. 2022 Nov;119:36-45. doi: 10.1016/j.neurobiolaging.2022.07.003. Epub 2022 Jul 21. Neurobiol Aging. 2022. PMID: 35964542 Free PMC article.
-
Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial.JAMA Neurol. 2022 Jun 1;79(6):565-574. doi: 10.1001/jamaneurol.2022.0983. JAMA Neurol. 2022. PMID: 35532913 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical